Abstract
An evaluation study was conducted in Chad to improve meningitis surveillance after the introduction of the serogroup A meningococcal conjugate vaccine. This project was carried out in four phases. Phase 1: Determine the actual costs of the current meningitis surveillance system; phase 2: Evaluate the performance and quality of the system; phase three: Determine the potential costs of scaling up the surveillance system to a feasible operational standard; and phase four: Use the results from Chad to develop a surveillance cost model that can be used for predicting the costs of surveillance strategies in other African meningitis belt countries.